Browse News
Filter News
Found 645 articles
-
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
2/20/2024
Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors.
-
Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
11/6/2023
Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to AL102, a Gamma Secretase Inhibitor (GSI), for the treatment of desmoid tumors (DT).
-
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
10/23/2023
Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that new data from the RINGSIDE study evaluating its lead investigational candidate AL102 for the treatment of desmoid tumors (DT) are being presented today at the European Society for Molecular Oncology (ESMO) Congress 2023, taking place October 20th to 24th in Madrid, Spain.
-
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
10/19/2023
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, announced the closing of its merger with Biosight, Ltd., pursuant to which Ayala acquired Biosight.
-
Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update
8/10/2023
Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced second-quarter 2023 financial results and provided a corporate update.
-
Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023
8/1/2023
Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a publicly-traded clinical-stage oncology company, today announced that it will present posters on its gamma secretase inhibitors AL102 and AL101 at the European Society for Molecular Oncology (ESMO) Congress 2023 , to be held in Madrid, Spain 20-24 October 2023.
-
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
7/27/2023
Ayala Pharmaceuticals, Inc. and Biosight Ltd. today announced they have entered into a definitive merger agreement pursuant to which Ayala will combine with Biosight in an all-stock transaction.
-
Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors
7/5/2023
Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that it has concluded an instructive and successful End-of-Phase-2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA).
-
Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
6/5/2023
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, announced further results from the Phase 2 segment of the RINGSIDE study evaluating AL102 in desmoid tumors.
-
Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
5/25/2023
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, announced updated results from Phase 2 of the RINGSIDE study evaluating AL102 in desmoid tumors.
-
Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update
5/23/2023
Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced first-quarter 2023 financial results and provided a corporate update.
-
Recursion Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer
5/16/2023
Recursion, a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced it has appointed David Mauro, M.D., Ph.D, as its Chief Medical Officer.
-
At 31.2% CAGR, Neoantigens Market Lead by Use of AI in Neoantigen Vaccine Development (2023-2028) | The Insight Partners
5/15/2023
The Insight Partners published latest research report on "Neoantigens Market Analysis Report, Size, Share, Trends, Growth & Demand Forecast to 2028 - COVID-19 Impact and Global Analysis By Treatment and Therapeutic Specialty”,
-
Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
4/27/2023
Ayala Pharmaceuticals, Inc. today announced that it will present a poster featuring data from the RINGSIDE study of AL102 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place June 2-6, 2023 in Chicago, Illinois and virtually.
-
Gennao Bio Announces Appointment of Christopher Duke as Chief Executive Officer
4/12/2023
Gennao Bio today announced the appointment of Christopher Duke, MBA, M.P.H., as chief executive officer, effective immediately.
-
Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee
3/3/2023
Ayala Pharmaceuticals, Inc. (OTCQX: ADXS) today announced that the Independent Data Monitoring Committee (IDMC) for its Phase 2/3 RINGSIDE study evaluating investigational new drug AL102 in desmoid tumors conducted a prespecified periodic review of data from the study and recommended that the study continue without modifications.
-
Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022
2/10/2023
Ayala Pharmaceuticals, Inc. (f/k/a Advaxis Inc.) (the “Company,” “New Ayala,” “we,” “us” or “our”) (OTCQX: ADXS), a clinical-stage oncology company, today announces financial results for the fiscal year ended October 31, 2022.
-
Advaxis and Ayala Pharmaceuticals Complete Merger
1/19/2023
Advaxis, Inc. (OTCQX: ADXS) today announced the completion of a previously announced merger with Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA).
-
Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer
1/12/2023
Advaxis, Inc. today announced an update on the Phase 1 clinical study evaluating ADXS-504, the company’s off-the-shelf neoantigen drug candidate, in patients with biochemically recurrent (early) prostate cancer that is being conducted at Columbia University Irving Medical Center.
-
Ayala Pharmaceuticals Presents Poster on AL102 in Desmoid Tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting
11/17/2022
Ayala Pharmaceuticals, Inc. today is announcing a poster presentation highlighting interim results from the Phase 2 segment / Part A of the RINGSIDE Pivotal Phase 2/3 clinical trial in desmoid tumors at the Connective Tissue Oncology Society Annual Meeting.